The US FDA would be responsible for clarifying its approach to regulating new non-addictive and non-opioid drugs for pain under draft legislation released by the Senate Health, Education, Labor and Pensions Committee April 4.
Through public meetings and guidances, FDA would be required to address issues ranging from designing clinical trials and use of...